Melanotan-2 (MT-2) is a synthetic cyclic heptapeptide analog of alpha-melanocyte-stimulating hormone (alpha-MSH). Most people know it as a tanning peptide, but that undersells what it does. MT-2 activates two distinct melanocortin receptor subtypes — MC1R and MC4R — producing effects that span skin pigmentation, sexual function, appetite regulation, body composition, and neuroprotection.
This guide ranks 6 research-backed MT-2 benefits by evidence strength. Every claim links to published data, and each section notes whether the evidence comes from human trials, animal models, or in-vitro work. No hype — just what the science shows.
For dosing protocols, see our Melanotan-2 Dosing Guide. For reconstitution and storage, see the Melanotan-2 Reconstitution Guide.
How Melanotan-2 Works
MT-2 is a non-selective melanocortin agonist. It binds to multiple melanocortin receptor subtypes, but its primary effects come through two:
MC1R (Melanocortin-1 Receptor) — expressed on melanocytes in the skin. Activation triggers eumelanin synthesis via the cAMP/PKA pathway, increasing dark pigment production. This is the tanning mechanism. A Phase I trial confirmed that just 5 low-dose subcutaneous injections produced measurable pigmentation changes in the face, upper body, and buttock (Dorr et al., 1996).
MC4R (Melanocortin-4 Receptor) — expressed in the hypothalamus and other CNS regions. Activation modulates sexual arousal, appetite, and energy expenditure. This is why MT-2 causes spontaneous erections, reduces food intake, and may influence body composition independently of caloric restriction.
Unlike PT-141 (bremelanotide), which was engineered for MC4R selectivity, MT-2 hits both receptors simultaneously. That makes it more versatile but also explains its broader side-effect profile. For a detailed comparison, see PT-141 vs Melanotan-2.
1. Skin Pigmentation (Tanning)
Evidence level: Strong — Human clinical trials
This is MT-2's most established benefit and the reason it was originally developed. Researchers at the University of Arizona created MT-2 as a potential skin cancer chemopreventive agent — the idea being that increased melanin production could protect fair-skinned individuals from UV damage.
In a Phase I single-blind, placebo-controlled trial, 3 male volunteers received subcutaneous MT-2 injections (0.01-0.03 mg/kg) on alternating days for 2 weeks. All subjects showed increased pigmentation in the face, upper body, and buttock — even without deliberate UV exposure (Dorr et al., 1996).
The mechanism is straightforward: MC1R activation on melanocytes upregulates tyrosinase activity, driving conversion of tyrosine to eumelanin (the dark, photoprotective form of melanin). This is the same pathway activated by UV exposure, but MT-2 amplifies it far beyond what sunlight alone achieves.
Practical takeaway: Most users report visible tanning within 7-14 days of a daily loading protocol (250-500 mcg/day subcutaneous). Even individuals with Fitzpatrick Type I-II skin (naturally very fair) achieve noticeable pigmentation. Minimal UV exposure — as little as 10-15 minutes of incidental sunlight — accelerates results significantly.
2. Sexual Function and Arousal
Evidence level: Strong — Human clinical trials (both sexes)
MT-2's sexual effects were discovered accidentally during the Phase I tanning trials when subjects reported spontaneous erections lasting 1-5 hours after injection. This led to a focused research program that ultimately produced PT-141.
In a double-blind, placebo-controlled crossover study of 20 men with psychogenic or organic erectile dysfunction, subcutaneous MT-2 initiated erections in 17 of 20 subjects — without any sexual stimulation. The effect was dose-dependent and distinct from PDE5 inhibitors because it works centrally, through hypothalamic MC4R activation rather than peripheral vasodilation (Hadley, 2005).
A separate placebo-controlled trial in men with organic ED found MT-2 initiated subjectively reported erections in 12 of 19 injections versus only 1 of 21 placebo doses (Wessells et al., 1998).
Critically, MT-2 also enhances sexual function in women. Research documented increased sexual desire and genital arousal in female subjects — a finding that led directly to the development of bremelanotide (PT-141), now FDA-approved for hypoactive sexual desire disorder in premenopausal women (Hadley & Dorr, 2006).
Practical takeaway: Sexual effects typically appear within hours of the first dose. They are dose-dependent — higher loading doses produce stronger effects. Unlike PDE5 inhibitors, MT-2 enhances desire and arousal (central mechanism), not just blood flow. For users primarily seeking sexual benefits, PT-141 may be a better option due to its MC4R selectivity and fewer pigmentation side effects.
3. Appetite Suppression
Evidence level: Moderate — Animal studies (no human trials)
MT-2 is a potent appetite suppressant through MC4R activation in the hypothalamus. This is well-established in rodent models but has not been tested in dedicated human appetite trials.
In rats, central administration of MT-2 suppressed food intake by approximately 30% in a dose-dependent manner. However, tachyphylaxis (tolerance) develops rapidly — within 3-5 days of continuous dosing, food intake returns to baseline levels (Cote et al., 2010).
The intermittent dosing solution is notable: when researchers alternated MT-2 infusion with off-periods, each reapplication produced a full anorectic response. This intermittent protocol resulted in robust fat and weight loss that exceeded continuous dosing (Cote et al., 2010).
Practical takeaway: Most human users report noticeable appetite suppression during the first 3-7 days of loading, consistent with the animal data showing rapid onset followed by tolerance. This is an incidental benefit rather than a primary use case. For dedicated appetite/weight management, melanocortin-based drugs like semaglutide or tirzepatide are far better studied in humans.
4. Body Composition
Evidence level: Moderate — Animal studies
Beyond acute appetite suppression, MT-2 appears to reduce body mass through mechanisms independent of caloric restriction. This is a subtle but important distinction from simple appetite suppression.
In a 40-day central infusion study in rats, MT-2 suppressed appetite dose-dependently, but food intake returned to control levels relatively quickly. Despite this, body mass remained persistently reduced in both MT-2 groups compared to controls. The researchers concluded that long-term body mass loss is only partially mediated by caloric restriction — melanocortin system activation appears to increase energy expenditure independently (Cote et al., 2017).
Practical takeaway: Some users report easier weight management during MT-2 cycles, which aligns with the animal data suggesting metabolic effects beyond appetite alone. However, these are rodent studies with central (brain) infusion — not subcutaneous injection. The relevance to human subcutaneous dosing is uncertain.
5. UV Photoprotection
Evidence level: Moderate — Mechanistic (supported by epidemiological data)
MT-2 was originally developed as a skin cancer prevention agent. The rationale: increased eumelanin acts as a natural broadband UV absorber, protecting DNA from ultraviolet radiation damage.
Melanin functions as both a physical UV shield and an antioxidant, scavenging reactive oxygen species generated by UV exposure. Epidemiological data consistently shows lower skin cancer incidence in individuals with higher baseline melanin (Brenner & Hearing, 2008).
By upregulating eumelanin production, MT-2 theoretically shifts fair-skinned individuals toward a more photoprotected phenotype. However, this benefit comes with an important caveat: MT-2 also stimulates melanocyte proliferation, which has raised concerns about potential effects on existing moles and nevi. See our Melanotan-2 Side Effects guide for the full safety breakdown.
Practical takeaway: The photoprotective benefit is real in principle — more melanin means more UV protection. But MT-2 is not approved for skin cancer prevention, and the melanocyte stimulation that produces tanning could theoretically promote existing atypical nevi. Always get a baseline dermatological exam before starting MT-2. See our Melanotan-2 Bloodwork Guide for monitoring recommendations.
6. Neuroprotection
Evidence level: Preliminary — Animal studies only
This is MT-2's least-discussed benefit, but the preclinical data is intriguing. Melanocortin receptors are widely expressed in the central and peripheral nervous system, and alpha-MSH analogs have demonstrated neuroprotective properties across multiple models.
MT-2 significantly enhanced recovery of sensory function following sciatic nerve crush injury in rats at a dose of 20 mcg/kg every 48 hours, subcutaneously. The same study showed partial protection from cisplatin-induced toxic neuropathy — a common chemotherapy side effect (Catania et al., 2003).
Practical takeaway: Neuroprotection is a preclinical finding only. No human studies exist for this application. It is included here for completeness because the mechanism — melanocortin receptor activation in neural tissue — is well-characterized, and it may explain some of the subjective cognitive effects users occasionally report.
